# Discuss treatment and driving safety

Published by Pawel Jozefiak. [About this project](https://adhd100.jock.pl/about/), [How we check sources](https://adhd100.jock.pl/methodology/)

- Canonical: https://adhd100.jock.pl/review-medication-driving-safety/
- Language: en
- First published: 2026-09-29
- Evidence checked: 2026-09-29, using AI-assisted source verification
- Clinical review: Not clinically reviewed
- Number 45 of 100 in the list: https://adhd100.jock.pl/#review-medication-driving-safety

Bring driving into your treatment review, looking at both attention problems and possible side effects.

**The number:** Ask your clinician if you are unsure whether driving on treatment is safe ([NHS, 2025](https://www.nhs.uk/medicines/methylphenidate-adults/common-questions-about-methylphenidate-for-adults/))

## The evidence

- How sure: Certainty of evidence: Very low certainty. Measured in people with ADHD.
- See this comparison on the evidence map: https://adhd100.jock.pl/evidence/#r-methylphenidate-adult-driving-clinician-rated-short
- Evidence grade: A. Grade A: moderate or high certainty evidence in people with ADHD, or an explicit ADHD guideline recommendation.
- Basis: NICE NG87 1.4.3 recommends discussing driving; EBI driving trials very low certainty; registry associations non-randomised
- Benefit: 55/100. The benefit score is an editorial prioritization for the general list, weighted by certainty. It is not a prediction of what will happen for you.

## Why it matters

ADHD is associated with higher transport risk, and a large registry study linked medication treatment with fewer transport accidents (adjusted rate ratio 0.88), though that does not prove cause. In EBI, small adult methylphenidate trials gave an uncertain driving result, SMD 0.53 with a confidence interval from -0.073 to 1.133 and very low certainty, over about 12 weeks or to trial endpoint. NICE recommends talking about driving after diagnosis, and NHS guidance notes that dizziness, sleepiness or sight problems from medicine can make driving unsafe.

## How to do it

1. Tell your prescriber whether you drive, and describe any attention worries or near misses.
2. Report sleepiness, dizziness, changes in vision or any other treatment effect that matters behind the wheel.
3. Ask how your symptoms and treatment affect your fitness to drive, in your circumstances.
4. Check the local licensing and reporting rules with an official source.

## Talk to a clinician first

Do not drive if symptoms or side effects make it unsafe. Medication does not guarantee safe driving, so get individual clinical advice and follow local licensing rules.

## Putting it into practice

### Start now

- 1 minute: Write down one driving moment that worried you, to take to your clinician.
- 5 minutes: Write down attention problems or side effects that could affect your driving.
- 15 minutes: Write a question about driving for your treatment review, and find the official local reporting guidance.

### What it looks like

- Mention a near miss at your review rather than discussing concentration only in the office.
- Ask whether dizziness or sleepiness could affect how safely you drive.

### Common mistakes

- A registry link cannot certify that you personally are safe to drive. Ask for an assessment of you.
- If you only look for symptom benefit, you can miss medicine effects that make driving worse. Report both.

### A structured start

**Include driving in the clinical review**

1. Describe driving-related difficulties and treatment effects.
2. Ask the clinician about fitness to drive in your situation.
3. Follow the agreed safety plan and local licensing requirements.

### Trusted how-to guides

- [Common questions about methylphenidate for adults](https://www.nhs.uk/medicines/methylphenidate-adults/common-questions-about-methylphenidate-for-adults/), NHS

## Sources

- [Common questions about methylphenidate for adults](https://www.nhs.uk/medicines/methylphenidate-adults/common-questions-about-methylphenidate-for-adults/), NHS, 2025 (Tier 1 guideline)
- [EBI-ADHD: companion data to Gosling et al., BMJ 2025, commit 86eff22a9ffb](https://raw.githubusercontent.com/CorentinJGosling/EBI-ADHD-UR-2025/86eff22a9ffb/datasets/dataset-ur-adhd.csv), BMJ / Gosling et al., 2025 (Tier 1 guideline)
- [Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making](https://pmc.ncbi.nlm.nih.gov/articles/PMC12651917/), BMJ, 2025 (Tier 1 guideline)
- [ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials](https://pmc.ncbi.nlm.nih.gov/articles/PMC12344785/), BMJ, 2025 (Tier 2 study)
- [Attention deficit hyperactivity disorder: diagnosis and management (NG87), recommendations](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations), NICE, 2019 (Tier 1 guideline)

---

General information about ADHD, not a diagnosis or an individual treatment plan. Tailoring changes the order of suggestions; it does not assess you. Medication decisions belong with you and a qualified clinician.

Report an error: meet@jock.pl

Reuse: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/